Market Research Blog

Next-generation sequencing refers to the identification of the nucleotides of DNA base pairs for the diagnosis of various diseases. Oncology is one of the important applications of next-generation sequencing. It is an advanced and faster method of sequencing. Clinical oncology next-generation sequencing includes kits & reagents, services, sequencing platforms, and sequencing products. The kits and reagents used for sequencing are expected to witness significant growth in the overall market.

North America is expected to be a prominent region in the global clinical oncology next-generation sequencing market owing to the presence of well-developed healthcare infrastructure and numerous technological advancements in the region. North America and Europe are expected to witness a significant growth rate in the clinical oncology next-generation sequencing market.

Synthesis Sequencing Technology to Hold a Major Market Value Share

Based on the technology, the clinical oncology next-generation sequencing market has been segmented into pyro sequencing, sequencing by synthesis (SBS), and Single-Molecule Real-Time Sequencing (SMRT), nanopore sequencing, ligation sequencing, and reversible dye termination sequencing. Synthesis sequencing is however expected to hold a significant share in the clinical oncology next-generation sequencing market.

Request Sample Copy of Report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-9543

Ion semiconductor sequencing is a method of DNA sequencing in which hydrogen ions are detected based on the polymerisation of DNA. Pyro-sequencing includes identifying the order of nucleotides in DNA based on the “sequencing by synthesis” principle, in which the sequencing is performed with the help of DNA polymerase. SBS is a technique used to determine the series of base pairs in DNA, which also known as DNA is sequencing.

There are various applications associated with clinical oncology next-generation treatment market. They include whole tumor genome sequencing, whole tumour exome sequencing, targeted tumour genome profiling, tumour transcriptome sequencing, tumour-normal comparisons, and other applications. Targeted tumor genome profiling is expected to hold a large share of the clinical oncology next-generation treatment market.

On the basis of end user, the clinical oncology next-generation sequencing market has been segmented into hospital laboratories, clinical research organisations, diagnostic laboratories, and others. Clinical research laboratories are expected to hold a large revenue share in the clinical oncology next-generation sequencing market.

Apart from the factors driving the clinical oncology next-generation sequencing market, there are few factors that are likely to hinder the overall growth of the clinical oncology next-generation sequencing market, such as high costs associated with the establishment of sequencing platforms, low quality of outsourcing services, and inadequate availability of sequencing platforms in some regional markets.

On the other hand, increasing biomedical research using clinical oncology, increasing government funding for life science projects, substantial decline in the prices of sequencing, and technological advancements in the field of sequencing are some of the major factors driving the growth of the clinical oncology next-generation sequencing market.

Ask from Market Research Expert @ https://www.futuremarketinsights.com/ask-question/rep-gb-9543

Tier 1 Companies Hold Nearly 3/5th Share of Global Market Value

The report tracks some of the key companies operating in the clinical oncology next-generation sequencing market such as QIAGEN N.V., Thermo Fisher Scientific., Pacific Biosciences of California, Inc., F. Hoffmann-La Roche Ltd Oxford Nanopore Technologies, Ltd., Takara Bio, Inc., Illumina Inc., PerkinElmer Inc.and Agilent Technologies, Inc. Thermo Fischer Scientific, Oxford Nanopore Technologies Ltd., and Illumina are expected to hold a signficant share of the clinical oncology next-generation sequencing market. These first tier companies hold a share of approximately 60% in the clinical oncology next-generation sequencing market.

CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET TAXONOMY

The global clinical oncology next generation sequencing market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach in front of the reader.

By Product

• Sequencing Platforms
• Sequencing Products
• Kits and Reagents
• Services

By Technology

• Ion Semiconductor Sequencing
• Pyro-Sequencing
• Synthesis Sequencing (SBS)
• Real Time Sequencing (SMRT)
• Ligation Sequencing
• Reversible Dye Termination Sequencing
• Nano-Pore Sequencing

For critical insights, request for PDF Brochure: https://www.futuremarketinsights.com/reports/brochure/rep-gb-9543

By Application

• Whole Tumor Genome Sequencing
• Whole Tumor Exome Sequencing
• Targeted Tumor Genome Profiling
• Tumor Transcriptome Sequencing
• Tumor-normal Comparisons
• Others

About FMI:

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact Us:
Future Market Insights,
Unit No: 1602-006,
Jumeirah Bay 2,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers,
Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs

The global conjunctivitis market size was predicted to be valued at US$ 1825.8 Million. The market is expected to reach nearly US$ 3208.7 Million by 2032, with a growing CAGR of 5.8% from 2022 to 2032. Swelling of conjunctiva (tissue covering white portion of eye) due to allergy is known as allergic conjunctivitis. Allergic conjunctivitis is caused due to allergens in patients such as household dust, mold spores, pollen from trees and grass, chemical scents (e.g., household detergents or perfume) and animal dander. Allergic conjunctivitis treatment includes medication for redness and inflammation caused to the conjunctiva.

International Ocular Inflammation Society (IOIS) describes allergic conjunctivitis as a type of ocular allergy that is further classified into two types, namely, seasonal allergic conjunctivitis and perennial allergic conjunctivitis. In the U.S., allergic conjunctivitis affects 15-20% of the general population while in other parts of the world, the estimates vary from 5-22% depending upon the topographical and demographic variations annually.

Allergic Conjunctivitis Treatment Market: Drivers and Restraints

Enhanced awareness about allergic conjunctivitis among the patients, medical community and people associated with the patients is one of the major driver for the growth of global allergic conjunctivitis market. Development in lifestyle and overall growth in number of patients suffering from allergic conjunctivitis are key factors boosting the growth of the global allergic conjunctivitis market.

Hence, treatments that can reduce allergic conjunctivitis are in demand. However, high cost associated with clinical trials acts as a major barrier for global allergic conjunctivitis market.

Request Sample PDF Brochure:

https://www.futuremarketinsights.com/reports/brochure/rep-gb-1318

Global Allergic Conjunctivitis Market: Overview

Rapid technological advancement, increase in the number of patients, increasing aging population, increasing demand for efficient drug types, increase in the incidence and prevalence of allergic conjunctivitis cases is expected to fuel growth of the global allergic conjunctivitis market during forecast period.

Global Allergic Conjunctivitis Market: Region-wise Outlook

Depending on geographic regions, global allergic conjunctivitis market is segmented into seven key regions: North America, Latin America, Eastern Europe, Western Europe, Asia Pacific Excluding Japan, Japan and Middle East & Africa. North America is the largest market owing to the high prevalence of allergic conjunctivitis in the region. According to estimates, approximately 60 Mn to 90 Mn Americans suffer from ocular allergy.

The APAC market is poised to grow rapidly in the near future owing to large population base which boosts demand for better healthcare facilities. Rapid urbanization and increasing particulate pollution has increased incidences of allergic conjunctivitis in several Asian countries such as India even though, the market has certain restraints such as awareness among general public regarding eye disorders and lack of health insurance.

Global Allergic Conjunctivitis Market: Key Players

Some of the key players in the global allergic conjunctivitis treatment market are Boehringer Ingelheim GmbH, Allergan Inc., Sanofi-Aventis, Novartis AG, Bausch & Lomb Inc., CIBA Vision Ophthalmics, Pfizer Inc., Merck & Co., Inc., and Santen Pharmaceuticals Co. Ltd.

Get In Touch With Our Team For 20% Flat Discount:

https://www.futuremarketinsights.com/ask-question/rep-gb-1318

The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to categories such as market segments, geographies, types, technology and applications.

Regional analysis includes 

• North America (U.S., Canada)
• Latin America (Mexico, Brazil, Rest of Latin America)
• Western Europe (Germany, Italy, Spain, France, U.K, Rest Of Western Europe)
• Eastern Europe (Poland, Russia, Rest of Eastern Europe)
• Asia Pacific (China, India, ASEAN, Australia & New Zealand)
• Japan
• Middle East and Africa (GCC countries, S. Africa, Rest of MEA)

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

Ask For Customization:

https://www.futuremarketinsights.com/customization-available/rep-gb-1318

ABOUT FUTURE MARKET INSIGHTS, INC.

Future Market Insights, Inc. is an ESOMAR-certified business consulting & market research firm, a member of the Greater New York Chamber of Commerce and is headquartered in Delaware, USA. A recipient of Clutch Leaders Award 2022 on account of high client score (4.9/5), we have been collaborating with global enterprises in their business transformation journey and helping them deliver on their business ambitions. 80% of the largest Forbes 1000 enterprises are our clients. We serve global clients across all leading & niche market segments across all major industries.

Now avail flexible Research Subscriptions, and access Research multi-format through downloadable databooks, infographics, charts, interactive playbook for data visualization and full reports through MarketNgage, the market intelligence engine from Future Market Insights. Sign Up for a 7 day free trial!

Contact:

Future Market Insights, Inc.

Christiana Corporate, 200 Continental Drive,

Suite 401, Newark, Delaware – 19713, USA

T: +1-845-579-5705

Enquiries: sales@futuremarketinsights.com

LinkedIn| Twitter| Blogs

The global advanced infusion systems market is likely to be valued at US$ 8,470.25 million in 2022 and is predicted to secure a slow-paced CAGR of 6.4% during the forecast period. The market is expected to grow at a value of US$ 15,820.03 million by 2032. Infusion systems are medical instruments and associated disposables, used to deliver fluids or drugs in solution to patient’s circulatory system in a controlled, precise and automated manner. There are different routes to introduce a drug into the patient’s system, of which, highly used mode is through intravenous, although subcutaneous, arterial and epidural infusion are preferred as per the requirement.

They are simple devices and gravity controllers that employ a clamping action to vary the flow of liquid under the force of gravity. This instrument was extensively used for medication purpose but, due to association of high mortality rates with it, advanced infusion systems were developed. Facilities like easy start up, visual monitoring, mobility of system, balanced and continues infusion of multiple medications at the same time, patient safety are a few factors which are boosting the growth of the potential market of advanced infusion systems over conventional ones.

Request Sample PDF Brochure:

https://www.futuremarketinsights.com/reports/brochure/rep-gb-2026

Advanced Infusion Systems Market: Drivers and Restraints

Overall increase in global population suffering from chronic disease, cancer, diabetes is the major factor that drives the market growth of global infusion systems market. Enormously developed technology in infusion system which eliminates user-related risks, higher bioavailability, safety, therapeutic effectiveness, increase in health care spending are also some other factors that drive the growth of the market.

To operate these automated infusion systems, a highly trained intelligent system is required. If this system is not trained properly, it can lead to increased morbidity and mortality rate which can restrain the growth of this market.

Advanced Infusion Systems Market: Overview

Over the last few decades volumetric and syringe pumps, the clinical and surgical industry, infusion systems, have been widely used for intravenous therapy (IV). Industry experts estimated that 80% of the hospitalized patients receive intravenous (IV) therapy. This demand is expected to increase in the coming years.

Growing incidence of chronic lifestyle disorders like cancer, diabetes and increased rate of aging population are the major factors that are expected to rise the demand for infusion pump market in forecast period. Increasing malnutrition in developing countries is expected to increase the demand for infusion pumps for critical nutrition. Hospitals are the largest end-users of infusion systems and account for over half of the market share.

Advanced Infusion Systems Market: Regional Overview

Region wise, the advanced infusion system market is segmented into regions namely, North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific, Japan and Middle East and Africa. North Americaholds the largest market share globally. The advanced infusion system market in Asia-Pacific and Latin America is expected to grow relatively fast in coming years. Factors expected to drive this growth are increase in population and increase in incidences of cancer, diabetes and asthma.

Get In Touch With Our Team For 20% Flat Discount:

https://www.futuremarketinsights.com/reports/brochure/rep-gb-2026

Advanced Infusion Systems Market: Key Players

Hospira, Inc., is a leading provider of infusion technologies globally. The key players in this markets are AngioDynamics, Inc., Animas Corporation, B. Braun Melsungen AG, Terumo Corporation and F. Hoffmann-La Roche Ltd. Infusion systems by Hospira, Inc. have operations in over 60 key markets across Europe, Asia and The Americas. Q Core Medical is a medical device company focused on the infusion pump market, which is expected to hold a large market share in the upcoming period.

Key Segments in The Advanced Infusion System Market

By Product:

• Elastomeric infusion system
• Volumetric infusion system- large volume and small volume pump
• Patient Controlled Analgesia pump
• Disposable infusion system
• Syringe infusion system
• Ambulatory infusion system
• Implantable infusion system

By Application:

• Chemotherapy
• Diabetes
• Pain management
• Asthma
• Clinical nutrition

By End-User:

• Hospitals
• Ambulatory Surgical Centers
• Diagnostic centers
• Bedside

By Region:

• North America
• Latin America
• Asia Pacific
• MEA
• Europe

Ask For Customization:

https://www.futuremarketinsights.com/customization-available/rep-gb-2026

ABOUT FUTURE MARKET INSIGHTS, INC.

Future Market Insights, Inc. is an ESOMAR-certified business consulting & market research firm, a member of the Greater New York Chamber of Commerce and is headquartered in Delaware, USA. A recipient of Clutch Leaders Award 2022 on account of high client score (4.9/5), we have been collaborating with global enterprises in their business transformation journey and helping them deliver on their business ambitions. 80% of the largest Forbes 1000 enterprises are our clients. We serve global clients across all leading & niche market segments across all major industries.

Now avail flexible Research Subscriptions, and access Research multi-format through downloadable databooks, infographics, charts, interactive playbook for data visualization and full reports through MarketNgage, the market intelligence engine from Future Market Insights. Sign Up for a 7 day free trial!

Contact:

Future Market Insights, Inc.

Christiana Corporate, 200 Continental Drive,

Suite 401, Newark, Delaware – 19713, USA

T: +1-845-579-5705

Enquiries: sales@futuremarketinsights.com

LinkedIn| Twitter| Blogs

The Atherosclerosis Market Size is anticipated to attain a valuation of US$ 58,236.4 Million by 2032, growing at a CAGR of 2.8% between 2022 and 2032, from a current value of US$ 44,183.8 Million in 2022. Atherosclerosis is the narrowing of the vein as a result of plaque build-up. Atherosclerosis is a particular kind of arteriosclerosis (stiffening or solidifying of the artery walls). The illness disturbs the stream of blood around the body, posturing genuine cardiovascular entanglements.

Atherosclerosis begins when the endothelium gets to be harmed, permitting LDL cholesterol to aggregate in the artery wall. The body sends macrophage white platelets to tidy up the cholesterol. However some of the time the cells stall out there at the influenced site. After some time this outcome in plaque being developed, comprising of terrible cholesterol (LDL cholesterol) and macrophage white platelets.

The plaque obstructs the corridor, upsetting the stream of blood around the body. This possibly causes blood clusters that can bring about existence undermining conditions, for example, heart assault, stroke and other cardiovascular ailments. Besides aging, aspects that upsurge the risk of atherosclerosis include: High blood pressure, high cholesterol, diabetes, obesity, smoking or other tobacco use, family history of early heart disease, lack of exercise and an unhealthy diet.

Request Sample PDF Brochure:

https://www.futuremarketinsights.com/reports/brochure/rep-gb-2523

Atherosclerosis Market: Drivers and Restraints

Growing incidence of heart attacks due to atherosclerosis or coronary heart disease is expected to increase demand for atherosclerosis treatment products. The rise in the aging population is expected to propel demand over the forecast period.

As per CDC (Centers for Disease Control and Prevention), coronary illness accounts for around 610,000 deaths per year in the United States- roughly being responsible for 1 of every 4 deaths reported. Coronary illness is the most widely recognized kind of coronary illness, killing more than 370,000 individuals every year. This increase in the baby boomer population is expected to add to the patient pool of atherosclerosis and thus in turn increase demand for treatment over the forecast period.

The development in atherosclerosis market is determined by expanded prevalence, obesity, sedentary lifestyle, hypertension, dyslipidemia, an especially decrease in high thickness cholesterol (HDL-C), and elevated cholesterol slim down. Medications to treat Atherosclerosis incorporates statins, angiotensin-converting enzyme (ACE) inhibitors, beta-blockers (BB), antiplatelets, calcium channel blockers (CCBs) and nitrates. With the dispatch of first-in-class pipeline molecules, for example, Yosprala (headache medicine and omeprazole), Praluent (alirocumab), Dalcetrapib (RG1658), Vorapaxar (SCH 530348), Canakinumab (ACZ885), Varespladib (A 002), Aliskiren, Generx, Xarelto (rivaroxaban), Anacetrapib (MK0859), and others are relied upon to get propelled in the forecasting period.

New contestants in the atherosclerosis market have indicated expanded adequacy and security profiles along with the reduction of CHD risk factors. Atherosclerosis or coronary artery disease showcase likewise has two different methods of treatment, which are coronary artery bypass grafting (CABG) and angioplasty.

The CAD death rate is very high contrasted with different maladies because of coronary events connected with CAD, including myocardial infections (MI), angina and strokes. In this way, the counteractive action of such events remains an undiscovered region of research and development for pharmaceutical organizations to bring novel medications into the market. However, the absence of definitive treatment, side effects and limited efficacy of the drugs available in the market and dependency in symptom based treatment in several cases is expected to hamper revenue growth of the atherosclerosis market over the forecast period.

Get In Touch With Our Team For 20% Flat Discount:

https://www.futuremarketinsights.com/reports/brochure/rep-gb-2523

Atherosclerosis Market: Overview

The global market for atherosclerosis is expected to witness robust growth owing to increasing incidence rate of the heart problems coupled with new treatment (branded and generic) approach.

Atherosclerosis Market: Region – wise Outlook

Globally the atherosclerosis market is segmented into seven key regions: North America, Latin America, Western Europe, Eastern Europe, Asia Pacific excluding Japan (APEJ), Japan and the Middle East and Africa (MEA). North America and Western Europe are expected to be the leading markets in the global atherosclerosis market. Rising treatment options among the aging population, prescription rates, and the maturing worldwide population are additionally considered vital drivers for this market. High awareness and easy available diagnostic tests are expected to boost demand for RSV infection treatment products in these regions.

Japan and APEJ are expected to follow next in terms of demand for the treatment of atherosclerosis market. Eastern Europe, Latin America, and MEA markets are also expected to witness above average growth over the forecast period. The absence of population-based studies in developing countries is a major challenge in the assessment of RSV-related infections in these countries.

Atherosclerosis Market: Participants

• GlaxoSmithKline plc.
• Merck & Co., Inc.
• F. Hoffmann-La Roche Ltd.
• Isis Pharmaceuticals, Inc.
• Anthera Pharmaceuticals
• Novartis AG
• Sanofi
• Johnson and Johnson
• Bayer AG
• The Medicine Company
• Cardium Therapeutics

Ask For Customization:

https://www.futuremarketinsights.com/customization-available/rep-gb-5863

ABOUT FUTURE MARKET INSIGHTS, INC.

Future Market Insights, Inc. is an ESOMAR-certified business consulting & market research firm, a member of the Greater New York Chamber of Commerce and is headquartered in Delaware, USA. A recipient of Clutch Leaders Award 2022 on account of high client score (4.9/5), we have been collaborating with global enterprises in their business transformation journey and helping them deliver on their business ambitions. 80% of the largest Forbes 1000 enterprises are our clients. We serve global clients across all leading & niche market segments across all major industries.

Now avail flexible Research Subscriptions, and access Research multi-format through downloadable databooks, infographics, charts, interactive playbook for data visualization and full reports through MarketNgage, the market intelligence engine from Future Market Insights. Sign Up for a 7 day free trial!

Contact:

Future Market Insights, Inc.

Christiana Corporate, 200 Continental Drive,

Suite 401, Newark, Delaware – 19713, USA

T: +1-845-579-5705

Enquiries: sales@futuremarketinsights.com

LinkedIn| Twitter| Blogs

The demand for therapeutic apheresis is estimated to rise at a CAGR of 6.8% during the forecast period. The global therapeutic apheresis market share is projected to be valued at US$ 2577.9 Mn in 2022 and is expected to reach US$ 5313 Mn by 2032. The demand for therapeutic apheresis is surging owing to growing incidences of chronic diseases and an increasing number of trauma and injury cases.Therapeutic apheresis is a procedure of the removal of a blood component from a patient using the apheresis technology. Therapeutic apheresis is used for the purpose of removing defective cells. Therapeutic apheresis is also used for the treatment of conditions in which a component or a pathogenic substance in the blood causes morbidity.

Basically there are three types of therapeutic apheresis procedure used, namely therapeutic plasma exchange (TPE), red blood cell exchange (RBCX) and cellular depletions. TPE is the removal of large volume of patient plasma and replacement of the plasma with appropriate fluids. TPE is commonly used for the treatment of autoimmune diseases or immune mediated diseases or disorders.

TPE removes monoclonal antibiotics, paraproteins, autoimmune antibodies and antigen-antibody complexes. Therapeutic apheresis selectively removes the substantial proportion of one or more components causing diseases.

Therapeutic Apheresis Market: Drivers and Restraints

Increasing use of therapeutic apheresis in the treatment of cancer will increase the growth of the global therapeutic apheresis market. In addition, increasing prevalence of chronic disorders and geriatric population will also increase the growth of the global therapeutic apheresis market.  Rise in healthcare expenditure will further boost the global therapeutic apheresis market. However, the lack of awareness and high cost of the procedures hampers the growth of the global therapeutic apheresis market.

Request Sample PDF Brochure:

https://www.futuremarketinsights.com/reports/brochure/rep-gb-5863

Therapeutic Apheresis Market: Overview

Therapeutic apheresis is a term which is used for the treatments and removal of chemicals, harmful proteins, or cells in the blood that contribute to disease. Therapeutic apheresis includes plasma exchange and cytapheresis. Therapeutic apheresis is helpful for those patients who are facing a variety of medical conditions.

Therapeutic apheresis is mainly used to treat patients suffering with blood disorders, kidney disorders, neurologic disorders and metabolic disorders. Based on technology, the global therapeutic apheresis market is segmented into centrifugation and membrane filtration. Based on end user, the market is segmented into hospitals, blood banks and specialty clinics.

Therapeutic Apheresis Market: Regional Outlook

Geographically, global therapeutic apheresis market is classified into regions viz. North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific, Japan, Middle East and Africa. North America dominated the global therapeutic apheresis market owing to its well-established healthcare infrastructure and high demand for plasma for production of plasma derived medicines.

Asia Pacific, with its considerably established therapeutic apheresis market in countries such as Japan and emerging economies such as India and China, is projected to witness exponential growth during the forecast period.

In addition, increasing rise in the prevalence of chronic diseases, high geriatric population, and increasing healthcare expenditure in this region will play the key role in the demand for therapeutic apheresis procedures in the next few years and this will surely increase the growth of the global therapeutic apheresis market.

Get In Touch With Our Team For 20% Flat Discount:

https://www.futuremarketinsights.com/ask-question/rep-gb-5863

Therapeutic Apheresis Market Key Players

Some of the players identified in global therapeutic apheresis market include Miltenyi Biotec, Fresenius Kabi USA, Terumo Bct, Inc., Baxter Healthcare Corporation, Medica S.p.A., and others.

The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to market segments such as geographies, application, and industry.

Regional analysis includes

• North America (U.S., Canada)
• Latin America (Mexico. Brazil)
• Western Europe (Germany, Italy, France, U.K, Spain)
• Eastern Europe (Poland, Russia)
• Asia Pacific (China, India, ASEAN, Australia & New Zealand)
• Japan
• Middle East and Africa (GCC Countries, S. Africa, Northern Africa)

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

Ask For Customization:

https://www.futuremarketinsights.com/customization-available/rep-gb-5863

ABOUT FUTURE MARKET INSIGHTS, INC.

Future Market Insights, Inc. is an ESOMAR-certified business consulting & market research firm, a member of the Greater New York Chamber of Commerce and is headquartered in Delaware, USA. A recipient of Clutch Leaders Award 2022 on account of high client score (4.9/5), we have been collaborating with global enterprises in their business transformation journey and helping them deliver on their business ambitions. 80% of the largest Forbes 1000 enterprises are our clients. We serve global clients across all leading & niche market segments across all major industries.

Now avail flexible Research Subscriptions, and access Research multi-format through downloadable databooks, infographics, charts, interactive playbook for data visualization and full reports through MarketNgage, the market intelligence engine from Future Market Insights. Sign Up for a 7 day free trial!

Contact:

Future Market Insights, Inc.

Christiana Corporate, 200 Continental Drive,

Suite 401, Newark, Delaware – 19713, USA

T: +1-845-579-5705

Enquiries: sales@futuremarketinsights.com

LinkedIn| Twitter| Blogs

The global anti-viral drugs market is expected to be valued at US$ 59,596.8 Million in 2022. The induction of the generic version of antiviral medicines and rising awareness about the availability of various vaccines for viral infections is affecting the growth throughout the forecast period. The overall demand for Anti-Viral Drugs is projected to grow at a CAGR of 3.9% between 2022 and 2032, totaling around US$ 87,675.36 Million by 2032.

Anti-viral drugs are medicines which are used specially for treating viral infections. Most anti-viral drugs are used for particular viral infections, similar to antibiotics, while a broad-spectrum anti-viral drug is effective against a varied range of viruses. Antiviral drugs do not kill their target pathogen, instead they inhibit the development of those viruses.

The global anti-viral drugs market is projected to register a moderate growth rate in the pharmaceutical market and which is anticipated to increase due to rise in awareness level, increase in the diseased population and introduction of new drugs with improved efficacy.

Some major patents are reaching their expiry during forecast period, such as for Combivir, Sustiva, Tenofovir, Tamiflu, Relenza and Telbivudine. The patent expiries of these blockbuster drugs is expected to trigger generic competition in the antivirals therapeutics market, which will make the market more competitive.

The late stage pipeline drugs are expected to enter the market, which will positively impact the market. Most antivirals are considered comparatively harmless to host, and therefore are used to treat infections. They are different from viricides, which are not used for medication but can destroy or deactivate virus particles, either outside or inside the body.

The anti-viral drugs are used in the treatment of patients suffering from herpes viruses, HIV, influenza A and B viruses and the hepatitis B and C viruses.

Request Sample Report:

https://www.futuremarketinsights.com/reports/sample/rep-gb-1951

Anti-viral Drugs Market: Drivers and Restraints

As of October 2013, according to WHO, there were around 35.3 Mn people globally, infected with HIV. Therefore, increased viral infection incidences is one of the important factors that drives the anti-viral drugs market growth. Because of the solid R&D activities, newer and advanced treatments and formulations, such as vaccines, combination therapy and others, are being introduced in the market.

Hence, strong R&D is one of the crucial factors in the anti-viral drugs market growth. On the other hand, high risk of failure, high cost of R&D and therapy, and government austerity are some of threats expected to hinder the growth of market.

These are some factors anticipated to fuel growth of global anti-viral drugs market within the forecast period of 2016-2026. However, increasing usage of natural products and high cost of developing drugs are the key challenges faced by the market.

Anti-viral Drugs Market: Overview

The generic market of anti-viral drugs is presently dominated by products such as didanosine, zidovudine, lamivudine and stavudine. The biggest driver of overall anti-viral drugs market is Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS) therapeutic sales which accounted for more than half the share of the market 2010.

At the end of 2012, 9.7 million people in low-income and middle-income countries were on antiretroviral treatment (ART). According to WHO, in 2012, number of patients on ART increased by 1.6 Mn, the largest increase in one year.

Nearly four out of five people were freshly put on treatment in the sub-Saharan Africa. In 21 African countries with a high burden of HIV, two out of three people in need are receiving treatment, and two out of three positive pregnant women are receiving antiretroviral drugs to prevent HIV transmission to their infants.

Ask For Customization:

https://www.futuremarketinsights.com/customization-available/rep-gb-1951

Anti-viral Drugs Market: Regional Overview

Region wise, the global anti-viral drugs market is classified into regions namely, North America, Eastern Europe, Western Europe, Latin America, Japan, Asia-Pacific, Middle East and Africa. According to WHO, in countries with Major ART scale-up such as Brazil or China, the death rate among people living with HIV has decreased by 80%. In 2015, in India the number of people living with HIV were 2.1 Mn and in U.S. the number was around 1.2 Mn in the year 2013.

Anti-viral Drugs Market: Key Players

Some of the key players in global anti-viral drugs market, which are focusing on general molecular mechanisms of antiviral drugs rather than therapies for individual viruses, include Roche, Gilead, GlaxoSmithKline, Bristol-Myers-Squibb, Abbott, AstraZeneca, Cipla, Schering-Plough, Johnson & Johnson, Merck & Co and others.

Key Segments Covered in the Anti-Viral Drugs Industry Analysis

Anti-Viral Drugs Market by Product type:

• Hepatitis-C antivirals
• HIV antivirals
• Herpes antivirals
• Hepatitis-B antivirals
• Influenza antivirals
• Others (Pneumonia, Flu, etc.)

Anti-Viral Drugs Market by End-user:

• Hospitals
• Clinics
• Ambulatory Surgical Centers

Anti-Viral Drugs Market by Region:

• North America Anti-Viral Drugs Market
• Latin America Anti-Viral Drugs Market
• Europe Anti-Viral Drugs Market
• Asia Pacific Anti-Viral Drugs Market
• The Middle East & Africa Anti-Viral Drugs Market

Get In Touch With Our Team For 20% Flat Discount:

https://www.futuremarketinsights.com/ask-question/rep-gb-1951

ABOUT FUTURE MARKET INSIGHTS, INC.

Future Market Insights, Inc. is an ESOMAR-certified business consulting & market research firm, a member of the Greater New York Chamber of Commerce and is headquartered in Delaware, USA. A recipient of Clutch Leaders Award 2022 on account of high client score (4.9/5), we have been collaborating with global enterprises in their business transformation journey and helping them deliver on their business ambitions. 80% of the largest Forbes 1000 enterprises are our clients. We serve global clients across all leading & niche market segments across all major industries.

Now avail flexible Research Subscriptions, and access Research multi-format through downloadable databooks, infographics, charts, interactive playbook for data visualization and full reports through MarketNgage, the market intelligence engine from Future Market Insights. Sign Up for a 7 day free trial!

Contact:

Future Market Insights, Inc.

Christiana Corporate, 200 Continental Drive,

Suite 401, Newark, Delaware – 19713, USA

T: +1-845-579-5705

Enquiries: sales@futuremarketinsights.com

LinkedIn| Twitter| Blogs

It is anticipated that the global veterinary antibiotics market is worth US$ 10,904.3 million in 2022. The veterinary antibiotics market is expected to expand at a sluggish CAGR of 5.8%, and reach US$ 20,277.5 million by 2032. Over the past few years animal antibiotics have accounted for major share in animal health industry owing to the rising need to treat, control or prevent animals against diseases. These are also used as growth promoters and play a vital role in maintaining animal health. Antibiotics are generally the anti-bacterial compounds that have a direct action on bacteria, thereby preventing the infection in livestock and companion animals.

Growing concerns over antibiotic resistance in human beings coupled with rising demand for milk, eggs and meat is influencing the veterinary antibiotic market across the globe. Rising prevalence of zoonotic disease worldwide is one of the major factor fueling the demand for veterinary antibiotics both in livestock animals as well as companion animals.

However, many farm and pet owners supported by veterinary healthcare activists are shifting towards vaccines owing to the harmful effects, such as antibiotic resistance, caused by long term usage of antibiotics. Also, stringent regulations imposed by FDA on use of prescribed antibiotics by the veterinarians is also hindering the market for veterinary antibiotics at present. Whereas in long run, regulations imposed by U.S. FDA are anticipated to pace the demand for these antibiotics.

Request Sample PDF Brochure:

https://www.futuremarketinsights.com/reports/brochure/rep-gb-4295

Veterinary Antibiotics Market: Drivers and Restraints

Some of the factors such as rising awareness about zoonotic disease, rising incidence of disease outbreaks in animals, growing demand for animal derived food products, implementation of stringent regulations to prevent animal diseases and elevating animal population and pet adoption are anticipated to drive the market for veterinary antibiotics across the globe. Also, the growing demand for pet health insurance coupled with rise in healthcare expenditure is propelling the demand for veterinary antibiotics globally.

However, increasing antibiotic resistance among food producing animals along with regulatory authorities restricting their use is restraining the growth of veterinary antibiotics market. Also, presence of competitive replacement products such as vaccines and probiotics are also limiting the usage of antibiotics to treat animals on large scale.

Veterinary Antibiotics Market: Overview

The market for the veterinary antibiotics is increasing due to the growing animal healthcare industry coupled with continuous development in this sector. On the basis of product type, tetracycline is anticipated to hold the largest market share in veterinary antibiotics market on the account of widespread use in food producing animals. Also, the rising awareness among people regarding essential pet health care is facilitating the market for veterinary antibiotics.

Get In Touch With Our Team For 20% Flat Discount:

https://www.futuremarketinsights.com/ask-question/rep-gb-4295

Veterinary Antibiotics Market: Regional Overview

On the basis of region, veterinary antibiotics market is segmented into North America, Latin America, Asia-Pacific excluding Japan, Eastern Europe, and Western Europe, Japan MEA and others. Among these, North America accounts for major share in veterinary antibiotics market, whereas, Asia-Pacific is anticipated to register the fastest growth at highest CAGR during the forecast period owing to presence of lenient regulations. However, unlike developed countries, the developing nations are projected to experience large demand for veterinary antibiotics due to less stringent regulations imposed on their usage.

Veterinary Antibiotics Market: Key Players

Some of the key players in the veterinary antibiotics market involves Zoetis, Inc., Merck & Co., Inc., Bayer AG, Sanofi, Eli Lilly and Company, Ceva Sante Animale and others.

The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to categories such as market segments, geographies, type of product and applications.

Ask For Customization:

https://www.futuremarketinsights.com/customization-available/rep-gb-4295

ABOUT FUTURE MARKET INSIGHTS, INC.

Future Market Insights, Inc. is an ESOMAR-certified business consulting & market research firm, a member of the Greater New York Chamber of Commerce and is headquartered in Delaware, USA. A recipient of Clutch Leaders Award 2022 on account of high client score (4.9/5), we have been collaborating with global enterprises in their business transformation journey and helping them deliver on their business ambitions. 80% of the largest Forbes 1000 enterprises are our clients. We serve global clients across all leading & niche market segments across all major industries.

Now avail flexible Research Subscriptions, and access Research multi-format through downloadable databooks, infographics, charts, interactive playbook for data visualization and full reports through MarketNgage, the market intelligence engine from Future Market Insights. Sign Up for a 7 day free trial!

Contact:

Future Market Insights, Inc.

Christiana Corporate, 200 Continental Drive,

Suite 401, Newark, Delaware – 19713, USA

T: +1-845-579-5705

Enquiries: sales@futuremarketinsights.com

LinkedIn| Twitter| Blogs

The global thoracolumbar stabilization devices market size is projected to be appraised at US$ 2,007.7 million by 2032, up from US$ 1,149.6 million in 2022, advancing at a CAGR of 5.2% from 2022 to 2032.Thoracolumbar is related to the thoracic and lumbar region of the spine. Thoracolumbar stabilization devices are used to reduce or eliminate the instability in the spine regions. These devices are an alternative method for the spinal fusion.

Thoracolumbar stabilization procedure retains some of the mobility in the spine, whereas fusion eliminate all the movement with complete stabilization. These devices also help in providing a firm support to the thoracic spine and straightening the curve.

Thoracolumbar Stabilization Devices Market: Drivers and Restraints

Thoracolumbar stabilization devices market is expected to be driven by the increasing prevalence of spine injury and fractures. Increasing demand for non-invasive surgical procedures is also expected to boost the growth of thoracolumbar stabilization devices market. Increasing prevalence of spine deformities among older population is also expected to boost the growth of thoracolumbar stabilization devices market.

High initial cost associated with these devices can be a restraint to the growth of thoracolumbar stabilization devices market.

Request Sample PDF Brochure:

https://www.futuremarketinsights.com/reports/brochure/rep-gb-4001

Thoracolumbar Stabilization Devices Market: Overview

Thoracolumbar stabilization devices market is expected to show significant growth over the forecast period. Spinal injury and chronic back pain are among the most prevalence conditions and increasing prevalence of these conditions is expected to drive the growth of thoracolumbar stabilization devices market.

Titanium devices segment is expected to be highest revenue generating market as these devices are light in weight and more dynamic in nature. Posterior thoracolumbar stabilization devices are expected to generate higher revenue than anterior devices as generally all surgical stabilization of thoracolumbar region starts with the posterior implant.

Market of thoracolumbar stabilization devices is expected to be continuously growing due to cost effectiveness and better management of disease as compare to analgesics. These devices are available in variety of shape and size and provide options to choose among variety which is expected to increase the revenue of thoracolumbar stabilization devices market.

Thoracolumbar Stabilization Devices Market: Region Wise Outlook

Geographically, the global thoracolumbar stabilization devices market can be segmented into the regions: North America, Latin America, Western Europe, Eastern Europe, Asia Pacific excluding Japan, Japan and Middle East & Africa. North America is biggest and most attractive market for the thoracolumbar stabilization devices due to presence of major players, awareness among people, better healthcare infrastructure and reimbursement policies.

Followed by which is Europe. Asia Pacific region is expected to be fastest growing thoracolumbar stabilization devices market due to large patient pool, increasing healthcare infrastructure and awareness among people.

Get In Touch With Our Team For 20% Flat Discount:

https://www.futuremarketinsights.com/ask-question/rep-gb-4001

Thoracolumbar Stabilization Devices Market: Key Players

Some of the market participants in the global thoracolumbar stabilization devices market are, B. Braun Melsungen AG, Zimmer, Inc., Coligne AG, Yellowsteps SAS, Medyssey Co. Ltd., DePuy Synthes Company, Aesculap Implant Systems, LLC, Ulrich Medical, Medtronic Public Limited Company and Stryker. Companies are focusing on advancement of devices and development of minimally invasive screws and roads.

The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to market segments such as geographies, application, and grades.

Key Segments Profiled in the Thoracolumbar Stabilization Devices Market Survey

By Device Type:

• Anterior Stabilization Device
• Posterior Stabilization Device
• Retractors

By Material:

• Titanium
• Stainless Steel

By End Use:

• Hospitals
• Clinics
• Ambulatory Surgical Centers

By Region:

• North America
• Latin America
• Asia Pacific
• Middle East and Africa
• Europe

Ask For Customization:

https://www.futuremarketinsights.com/customization-available/rep-gb-4001

ABOUT FUTURE MARKET INSIGHTS, INC.

Future Market Insights, Inc. is an ESOMAR-certified business consulting & market research firm, a member of the Greater New York Chamber of Commerce and is headquartered in Delaware, USA. A recipient of Clutch Leaders Award 2022 on account of high client score (4.9/5), we have been collaborating with global enterprises in their business transformation journey and helping them deliver on their business ambitions. 80% of the largest Forbes 1000 enterprises are our clients. We serve global clients across all leading & niche market segments across all major industries.

Now avail flexible Research Subscriptions, and access Research multi-format through downloadable databooks, infographics, charts, interactive playbook for data visualization and full reports through MarketNgage, the market intelligence engine from Future Market Insights. Sign Up for a 7 day free trial!

Contact:

Future Market Insights, Inc.

Christiana Corporate, 200 Continental Drive,

Suite 401, Newark, Delaware – 19713, USA

T: +1-845-579-5705

Enquiries: sales@futuremarketinsights.com

LinkedIn| Twitter| Blogs

According to a recent study by Future Market Insights (FMI), the global orthopaedic imaging equipment market is expected reach US$ 9.8 Bn in 2021. Sales are expected to increase at a CAGR of around 4.0% over the forecast period (2021-2031).

Orthopaedic imaging equipment is the medical imaging equipment used for bone scanning, implants scanning and is utilized for diagnosis purposes. Different imaging technologies such as X-rays, MRI, ultrasound, EOS and nuclear imaging are included in Orthopaedic imaging equipment.

Rising prevalence of Orthopaedic diseases and bone injuries, technological advancement in Orthopaedic imaging equipment devices, and rise in research and development activities by key manufacturers are factors driving the Orthopaedic imaging equipment market.

Numerous medical imaging modalities are currently enabling three-dimensional (3D) visualization with accuracy, and rapid diagnoses. Advancements in 3D imaging have led to development in computer-assisted detection (CAD) and image analysis applications. This is expected to boost the market for modality, primarily in tomographic imaging techniques.

Moreover, surgeons are using 3D imaging to plan surgeries, which has led to increased application of these systems. This is expected to increase the utilization of imaging equipment, especially across the U.S. and the U.K.

Consequently, these devices are also gaining high traction in Asia such as China and India due to growing demand for better health care infrastructure. Improving healthcare infrastructure and technological developments in these countries will increase the demand for 3D medical imaging equipment.

Request Sample PDF Brochure:

https://www.futuremarketinsights.com/reports/sample/rep-gb-1842

Key Takeaways from Orthopaedic Imaging Equipment Study

• In terms of product type, the X-ray systems is expected to account for 28.0%, expanding at a CAGR of 3.3% during the forecasted period.
• By indication, the acute injuries segment will contribute over 56.6% of sales in the global Orthopaedic imaging equipment market.
• Hospitals and radiology centers will, collectively, account for 68.2% of the market share in 2021.
• With the advancements in technologies as well as the increasing geriatric population, North America held the largest share of over 30.5% in 2021.
• India and China are expected to lead the growth of South and East Asia in the global Orthopaedic imaging equipment market.

“Growing geriatric population, increasing incidence of bone fractures and orthopaedic illness, and increasing need for 3D medical imaging technology are expected to fuel the demand for Orthopaedic imaging equipment over the forthcoming decade,” says the FMI Analyst

Who is winning?

The key market players covered by FMI include General Electric Healthcare Limited, Siemens AG, Esaote SPA, Hitachi Ltd, Koninklijke Philips N.V, PLANMED OY, EOS imaging, Canon Medical Systems Corporation, Carestream Health and Neusoft Corporation.

Some of the leading manufacturers of the Orthopaedic imaging equipment market are focusing on the development of advanced and cost-effective products establishing distribution agreements, collaborations and partnerships strategies for global expansion objectives, thereby, enhancing their market presence.

• In September 2021, GE Healthcare acquired BK Medical for $1.45Bn to expand its $3bn ultrasound business from diagnostics to surgical and therapeutic interventions.
• In April 2016, Hitachi Ltd Company integrated Hitachi Medical Corporation and Hitachi Aloka medical into Hitachi Ltd to strengthen its manufacturing operations and to develop low-cost medical devices.

Inquire Before Buying Research Report:

https://www.futuremarketinsights.com/ask-question/rep-gb-1842

Want more insights?

Future Market Insights brings the comprehensive research report on forecasted revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2016 to 2031. The global Orthopaedic Imaging Equipment market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader. The study provides compelling insights on Orthopaedic imaging equipment segment based on Product (X-Ray System, CT-Scanner, MRI System, EOS Imaging Systems, Ultrasound, Nuclear Imaging Systems), Indication (Acute injuries {Sports injuries, Trauma cases}, Chronic Disorders { Osteoarthritis, Osteoporosis, Prolapsed Disc, Degenerative joint diseases} and Others), and End User (Hospitals, Radiology Centers, Emergency Care Facility, Ambulatory Surgical Center) across seven major regions.

ABOUT FUTURE MARKET INSIGHTS, INC.

Future Market Insights, Inc. is an ESOMAR-certified business consulting & market research firm, a member of the Greater New York Chamber of Commerce and is headquartered in Delaware, USA. A recipient of Clutch Leaders Award 2022 on account of high client score (4.9/5), we have been collaborating with global enterprises in their business transformation journey and helping them deliver on their business ambitions. 80% of the largest Forbes 1000 enterprises are our clients. We serve global clients across all leading & niche market segments across all major industries.

Now avail flexible Research Subscriptions, and access Research multi-format through downloadable databooks, infographics, charts, interactive playbook for data visualization and full reports through MarketNgage, the market intelligence engine from Future Market Insights. Sign Up for a 7 day free trial!

Contact:

Future Market Insights, Inc.

Christiana Corporate, 200 Continental Drive,

Suite 401, Newark, Delaware – 19713, USA

T: +1-845-579-5705

Enquiries: sales@futuremarketinsights.com

LinkedIn| Twitter| Blogs